News FocusBiomedicine

Gene Therapy on Trial

Science  12 May 2000:
Vol. 288, Issue 5468, pp. 951-957
DOI: 10.1126/science.288.5468.951

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

A flurry of reports and congressional hearings, sparked by the death of a volunteer in a study at the University of Pennsylvania in Philadelphia last fall, are due in the next few weeks. The Penn episode points up a central problem: The field still lacks an ideal vector. Many clinicians fear that support for gene therapy will buckle under the onslaught.

Related Content